Investigations of reported plasma amyloid b peptides and total tau protein assayed with immunomagnetic reduction in cognitively normal controls and patients with amnestic mild cognitive impairment and Alzheimer’s disease dementia
Charles SY Yang · 2025
Read Investigations of reported plasma amyloid b peptides and total tau protein assayed with immunomagnetic reduction in cognitively normal controls and patients with amnestic mild cognitive impairment and Alzheimer’s disease dementia by Charles SY Yang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11715426.txt.
Description
Charles Yang reviews three decades of blood test results for Alzheimer disease markers in a 2025 summary paper. Since 2012, many groups have used one sensitive method to measure two amyloid pieces and a protein called tau in blood. The method was applied to healthy older adults, people with mild memory loss, and people with full Alzheimer dementia.
Yang gathered the mean values reported in 30 studies, counting journal papers, conference talks, and three unpublished sets. He then checked how much the reported means varied from study to study. Wide swings would warn that the test is not yet steady enough for clinic use, while tight agreement would support it. The paper gives readers a clear view of how consistent this blood test path has been.
Catalog record
| CREATOR | Charles SY Yang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |